Compare BZUN & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZUN | RNA |
|---|---|---|
| Founded | 2007 | 2025 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.5M | 141.3M |
| IPO Year | 2014 | 2025 |
| Metric | BZUN | RNA |
|---|---|---|
| Price | $3.82 | $7.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $4.58 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 300.9K | 297.6K |
| Earning Date | 11-24-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.08 | $84.55 |
| Revenue Next Year | $7.45 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.07 | $7.54 |
| 52 Week High | $3.82 | $73.06 |
| Indicator | BZUN | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 72.38 | 30.90 |
| Support Level | $2.74 | $7.63 |
| Resistance Level | N/A | $8.50 |
| Average True Range (ATR) | 0.20 | 0.33 |
| MACD | 0.05 | 0.11 |
| Stochastic Oscillator | 92.79 | 22.92 |
Baozun Inc is engaged to provide its customers with end-to-end e-commerce solutions including the sales of apparel, home and electronic products, online store design and setup, visual merchandising and marketing, online store operations, customer services, warehousing and order fulfillment, as well as the holistic brand management, including tactic positioning, branding and marketing, retail and e-commerce operations, supply chain and logistics, and technology empowerment. It has two operating segments: E-Commerce (encompassing BEC and BZI) and Brand Management (representing BBM). The company generates maximum of its revenue from E-Commerce (encompassing BEC and BZI) segment.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.